title: Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.
abstract: Endocannabinoids and their attending cannabinoid type 1 (CB1) receptor have been implicated in animal models of post-traumatic stress disorder (PTSD). However, their specific role has not been studied in people with PTSD. Herein, we present an in vivo imaging study using positron emission tomography (PET) and the CB1-selective radioligand [(11)C]OMAR in individuals with PTSD, and healthy controls with lifetime histories of trauma (trauma-exposed controls (TC)) and those without such histories (healthy controls (HC)). Untreated individuals with PTSD (N=25) with non-combat trauma histories, and TC (N=12) and HC (N=23) participated in a magnetic resonance imaging scan and a resting PET scan with the CB1 receptor antagonist radiotracer [(11)C]OMAR, which measures the volume of distribution (VT) linearly related to CB1 receptor availability. Peripheral levels of anandamide, 2-arachidonoylglycerol, oleoylethanolamide, palmitoylethanolamide and cortisol were also assessed. In the PTSD group, relative to the HC and TC groups, we found elevated brain-wide [(11)C]OMAR VT values (F(2,53)=7.96, P=0.001; 19.5% and 14.5% higher, respectively), which were most pronounced in women (F(1,53)=5.52, P=0.023). Anandamide concentrations were reduced in the PTSD relative to the TC (53.1% lower) and HC (58.2% lower) groups. Cortisol levels were lower in the PTSD and TC groups relative to the HC group. Three biomarkers examined collectively--OMAR VT, anandamide and cortisol--correctly classified nearly 85% of PTSD cases. These results suggest that abnormal CB1 receptor-mediated anandamide signaling is implicated in the etiology of PTSD, and provide a promising neurobiological model to develop novel, evidence-based pharmacotherapies for this disorder.
authors.affiliation: Molecular Imaging Program, Department of Psychiatry and Radiology, New York University School of Medicine, New York, NY 10016, USA. alexander.neumeister@nyumc.org
authors.forename: A
authors.initials: A
authors.lastname: Neumeister
authors.forename: M D
authors.initials: MD
authors.lastname: Normandin
authors.forename: R H
authors.initials: RH
authors.lastname: Pietrzak
authors.forename: D
authors.initials: D
authors.lastname: Piomelli
authors.forename: M Q
authors.initials: MQ
authors.lastname: Zheng
authors.forename: A
authors.initials: A
authors.lastname: Gujarro-Anton
authors.forename: M N
authors.initials: MN
authors.lastname: Potenza
authors.forename: C R
authors.initials: CR
authors.lastname: Bailey
authors.forename: S F
authors.initials: SF
authors.lastname: Lin
authors.forename: S
authors.initials: S
authors.lastname: Najafzadeh
authors.forename: J
authors.initials: J
authors.lastname: Ropchan
authors.forename: S
authors.initials: S
authors.lastname: Henry
authors.forename: S
authors.initials: S
authors.lastname: Corsi-Travali
authors.forename: R E
authors.initials: RE
authors.lastname: Carson
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
mesh_terms: D000328:Adult; D000577:Amides; D000704:Analysis of Variance; D001095:Arachidonic Acids / Q000097:blood / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D063388:Endocannabinoids / Q000097:blood / Q000378:metabolism; D004983:Ethanolamines / Q000378:metabolism; D005260:Female; D005989:Glycerides / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D007093:Imidazoles / Q000378:metabolism; D016015:Logistic Models; D008297:Male; D010169:Palmitic Acids / Q000378:metabolism; D010880:Piperidines / Q000493:pharmacokinetics; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D011720:Pyrazoles / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D013313:Stress Disorders, Post-Traumatic / Q000000981:diagnostic imaging / Q000473:pathology*; D055815:Young Adult
chemical_list: C515663:4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; D000577:Amides; D001095:Arachidonic Acids; D063388:Endocannabinoids; D004983:Ethanolamines; D005989:Glycerides; D007093:Imidazoles; D010169:Palmitic Acids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C018353:oleoylimidazolide; C005958:palmidrol; C094503:glyceryl 2-arachidonate; C078814:anandamide; D006854:Hydrocortisone